GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (OHEL:FARON) » Definitions » PB Ratio

Faron Pharmaceuticals Oy (OHEL:FARON) PB Ratio : 157.31 (As of Dec. 15, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Faron Pharmaceuticals Oy PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-15), Faron Pharmaceuticals Oy's share price is €2.045. Faron Pharmaceuticals Oy's Book Value per Share for the quarter that ended in Jun. 2024 was €0.01. Hence, Faron Pharmaceuticals Oy's PB Ratio of today is 157.31.

Warning Sign:

Faron Pharmaceuticals Oy stock PB Ratio (=154.55) is close to 10-year high of 154.55

The historical rank and industry rank for Faron Pharmaceuticals Oy's PB Ratio or its related term are showing as below:

OHEL:FARON' s PB Ratio Range Over the Past 10 Years
Min: 1.97   Med: 9.71   Max: 154.55
Current: 154.55

During the past 12 years, Faron Pharmaceuticals Oy's highest PB Ratio was 154.55. The lowest was 1.97. And the median was 9.71.

OHEL:FARON's PB Ratio is ranked worse than
99.53% of 1281 companies
in the Biotechnology industry
Industry Median: 2.48 vs OHEL:FARON: 154.55

During the past 3 years, the average Book Value Per Share Growth Rate was -74.00% per year.

During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Faron Pharmaceuticals Oy was 63.00% per year. The lowest was -74.00% per year. And the median was -59.90% per year.

Back to Basics: PB Ratio


Faron Pharmaceuticals Oy PB Ratio Historical Data

The historical data trend for Faron Pharmaceuticals Oy's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faron Pharmaceuticals Oy PB Ratio Chart

Faron Pharmaceuticals Oy Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 88.08 - 58.28 - -

Faron Pharmaceuticals Oy Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 91.54

Competitive Comparison of Faron Pharmaceuticals Oy's PB Ratio

For the Biotechnology subindustry, Faron Pharmaceuticals Oy's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Faron Pharmaceuticals Oy's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Faron Pharmaceuticals Oy's PB Ratio distribution charts can be found below:

* The bar in red indicates where Faron Pharmaceuticals Oy's PB Ratio falls into.



Faron Pharmaceuticals Oy PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Faron Pharmaceuticals Oy's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2024)
=2.045/0.013
=157.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Faron Pharmaceuticals Oy  (OHEL:FARON) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Faron Pharmaceuticals Oy PB Ratio Related Terms

Thank you for viewing the detailed overview of Faron Pharmaceuticals Oy's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Faron Pharmaceuticals Oy Business Description

Traded in Other Exchanges
Address
Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested for the prevention of complications that arise from cytokine release syndrome, or hyperinflammatory conditions.

Faron Pharmaceuticals Oy Headlines

No Headlines